Forest Ray received his PhD in systems biology from Columbia University, where he developed tools to match drug side effects to other diseases. He has since worked as a journalist and science writer, covering topics from rare diseases to the intersection between environmental science and social justice. He currently lives in Long Beach, California.
Compared with an infusion into the vein, injecting Actemra (tocilizumab) under the skin offers people with systemic and polyarticular juvenile idiopathic arthritis (JIA) similar performance in a more convenient route ... Read more
Versus Arthritis has funded three more years of research into therapies for juvenile arthritis and related conditions at the U.K. Experimental Arthritis Treatment Centre for Children (EATC4Children) with a £600,000 ... Read more
U.K. charity Juvenile Arthritis Research has published an informational booklet called “My JIA,” a resource for children with juvenile idiopathic arthritis (JIA), their families, caregivers, and schools. The booklet, available ... Read more
Early treatment with biologics is increasingly being given to children newly diagnosed with systemic juvenile idiopathic arthritis (sJIA) in the U.S., but their use varies widely among hospitals and a reliance ... Read more
Young children with polyarticular juvenile idiopathic arthritis (pJIA) maintained effective vaccination against diphtheria and tetanus even after starting treatment with Orencia (abatecept) for up to two years, according to a ... Read more
Treatment with Ilaris (canakinumab) can be discontinued without relapse in some children with systemic juvenile arthritis (sJIA), according to a recent small study. Sustained remission specifically appears to be more ... Read more